MX2023003855A - Metodos para reducir la expresion de apociii. - Google Patents

Metodos para reducir la expresion de apociii.

Info

Publication number
MX2023003855A
MX2023003855A MX2023003855A MX2023003855A MX2023003855A MX 2023003855 A MX2023003855 A MX 2023003855A MX 2023003855 A MX2023003855 A MX 2023003855A MX 2023003855 A MX2023003855 A MX 2023003855A MX 2023003855 A MX2023003855 A MX 2023003855A
Authority
MX
Mexico
Prior art keywords
methods
fcs
reducing apociii
shtg
fpl
Prior art date
Application number
MX2023003855A
Other languages
English (en)
Inventor
Veronica J Alexander
Sotirios Tsimikas
Stanley T Crooke
Richard S Geary
Brett P Monia
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of MX2023003855A publication Critical patent/MX2023003855A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente se proporcionan métodos para administrar ISIS 678354 para mejorar el síndrome de quilomicronemia familiar (FCS), la lipodistrofia parcial familiar (FPL), la hipertrigliceridemia grave (SHTG), reducir el ARN de APOCIII o reducir la proteína APOCIII en un sujeto humano que lo necesita. En determinados casos, los métodos son útiles para mejorar al menos un síntoma de FCS, FPL o SHTG. Dichos síntomas de FCS incluyen, de modo no taxativo, elevaciones graves en los quilomicrones y niveles extremadamente elevados de TG (que siempre alcanzan muy por encima de 1000 mg/dL y no pocas veces aumentan hasta 10 000 mg/dL o más) con episodios de dolor abdominal, fatiga física, dificultad para pensar, diarrea, pancreatitis aguda recurrente, xantomas cutáneos eruptivos, y hepatoesplenomegalia.
MX2023003855A 2020-10-02 2021-09-24 Metodos para reducir la expresion de apociii. MX2023003855A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063087095P 2020-10-02 2020-10-02
PCT/US2021/052001 WO2022072244A1 (en) 2020-10-02 2021-09-24 Methods for reducing apociii expression

Publications (1)

Publication Number Publication Date
MX2023003855A true MX2023003855A (es) 2023-04-14

Family

ID=80950871

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003855A MX2023003855A (es) 2020-10-02 2021-09-24 Metodos para reducir la expresion de apociii.

Country Status (10)

Country Link
US (1) US20240033280A1 (es)
EP (1) EP4221720A1 (es)
JP (1) JP2023543898A (es)
KR (1) KR20230079394A (es)
CN (1) CN116348125A (es)
AU (1) AU2021353849A1 (es)
BR (1) BR112023004012A2 (es)
IL (1) IL300882A (es)
MX (1) MX2023003855A (es)
WO (1) WO2022072244A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024097861A1 (en) * 2022-11-02 2024-05-10 Ionis Pharmaceuticals, Inc. Methods for modulating complement factor b expression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598227B2 (en) * 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
CN108743943A (zh) * 2013-02-14 2018-11-06 Ionis制药公司 对脂蛋白脂肪酶缺乏群体中的载脂蛋白c-iii(apociii)表达的调节
RU2737719C2 (ru) * 2015-02-27 2020-12-02 Ионис Фармасьютикалз, Инк. Модулирование экспрессии аполипопротеина с-iii (аросiii) у пациентов с липодистрофией

Also Published As

Publication number Publication date
EP4221720A1 (en) 2023-08-09
CN116348125A (zh) 2023-06-27
AU2021353849A1 (en) 2023-03-23
BR112023004012A2 (pt) 2023-04-25
JP2023543898A (ja) 2023-10-18
IL300882A (en) 2023-04-01
WO2022072244A1 (en) 2022-04-07
US20240033280A1 (en) 2024-02-01
AU2021353849A8 (en) 2023-03-30
KR20230079394A (ko) 2023-06-07

Similar Documents

Publication Publication Date Title
Braga et al. Clinical evidence for pharmaconutrition in major elective surgery
MX2023003855A (es) Metodos para reducir la expresion de apociii.
Steurer-Stey et al. Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review
BR112014009837A8 (pt) uso eficaz da levedura e extrato de levedura
Lee et al. Intestinal inflammation as a dysbiosis of energy procurement: new insights into an old topic
Cechnicki et al. The influence of early psychosocial intervention on the long-term clinical outcomes of people suffering from schizophrenia
Maltsev et al. Vitamin D and immunity
WO2022026092A3 (en) Method of treatment of neutrophil-driven inflammatory pathologies
Bonifacio et al. Clinical outcome of long-term home parenteral nutrition in non-oncological patients: a report from two specialised centres
BRPI0410761A (pt) uso de leucina, e, composição para administração entérica a pacientes
US20210340177A1 (en) Bioactive peptides having high binding affinity to human muscular nicotinic acetylcholine receptor
Khatami Sabzevar et al. The effect of short-term use of chamomile essence on muscle soreness in young girls after an exhaustive exercise
AU2019100077A4 (en) Treatment for gastrointestinal diseases, depression, and anxieties
张娟 et al. Effect of umbilical cord-derived mesenchymal stem cells on the expression of sex hormones CYR61 and CTGF in rabbits with premature ovarian failure
Sawada Editorial Comment to Clinical guidelines for interstitial cystitis/bladder pain syndrome.
Costa Botulinum toxin-A
Jiang et al. Mechanism of extracorporeal shock wave combined with platelet rich plasma in the treatment of articular cartilage injury in knee osteoarthritis rats based on the Sirt1/FoxO1 pathway
Mehl-Madrona Effects of adding acupuncture to group psychotherapy for anxiety
Badillo Botulinum toxin A
Alburaidi et al. LEVELS OF FEARS AMONG STUDENTS OF THE FIRST CYCLE OF BASIC EDUCATION IN OMAN: A STUDY ACCORDING TO THE" SPENCE" SCALE
Lebedev et al. Laparoscopic surgery for advanced peritonitis
Chen et al. Elastic band exercises improved sleep quality and depression of nursing home older adults in wheelchairs
Sleight The influence of mortality trials on the evolution of clinical practice
Olivier An update on the use of proteolytic enzymes as a means to reduce inflammation and pain
Sravya et al. ASSESSMENT OF RISK FACTORS ASSOCIATED WITH PANCREATITIS–A PROSPECTIVE CASE CONTROL STUDY